Roflumilast

Overview

Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC 50 s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1 , PDE4A4 , PDE4B1 , and PDE4B2 , respectively, without affecting PDE1 , PDE2 , PDE3 or PDE5 isoenzymes from various cells.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Depression | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > RSV

Product Information

• Catalog No.: HY-15455
• CAS No.: 162401-32-3
• Molecular Formula: C17H14Cl2F2N2O3
• Molecular Weight: 403.21
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.20 mM); Clear solution
• Availability: In-stock

Source

Original product source